Immunisation and the maturation of infant immune responses

Area of Science:

• Immunology
• Vaccinology
• Pediatric Infectious Diseases

Background:

• The fetal immune system matures early, with T and B cells capable of antigen response by 14 weeks gestation.
• Neonatal immune responses are effective against protein antigens but limited against carbohydrate antigens.
• Bacterial carbohydrate capsules contribute to invasive pediatric infections, posing a challenge for traditional vaccines.

Purpose of the Study:

• To address the limited immunogenicity of carbohydrate-only vaccines.
• To explore the efficacy of conjugate vaccine technology in overcoming carbohydrate antigen limitations.
• To highlight the success of existing conjugate vaccines and their application to new targets.

Main Methods:

• Development and application of conjugate vaccine technology, chemically coupling carbohydrate antigens to protein carriers.
• Clinical evaluation of conjugate vaccines, exemplified by Haemophilus influenzae type b (Hib) conjugate vaccines.
• Ongoing research and development of conjugate vaccines for other significant pathogens.

Main Results:

• Conjugate vaccine technology significantly enhances the immunogenicity of carbohydrate antigens.
• Haemophilus influenzae type b conjugate vaccines have demonstrated remarkable success, nearly eradicating invasive Hib disease in vaccinated populations.
• The success of Hib conjugate vaccines validates the broader application of this technology.

Conclusions:

• Conjugate vaccine technology is a breakthrough in overcoming the immunogenicity limitations of carbohydrate antigens.
• This approach has proven highly effective in preventing invasive bacterial infections, particularly in pediatric populations.
• Conjugate technology is being actively pursued for vaccines against other critical pathogens like Neisseria meningitidis and Streptococcus pneumoniae.